EQL Pharma invites to Capital Markets Day, March 7, 2025

EQL Pharma AB (publ), a leading Niche Pharmaceuticals Company, is pleased to invite investors and other interested parties to a Capital Markets Day (CMD) on Friday, March 7, 2025.

During the day EQL Pharma’s CEO Axel Schörling, Chief Commercial Officer Alexander Brising and Chief Business Development Officer Carl Lindgren will give an updated investor presentation. The presentations will be held in English.

During the presentation, EQL will share its new long term financial targets and strategic plan with a special focus on how the company plans to reach these new targets. Additionally, the Business Development, Sales and M&A approaches will be covered in more detail as well as the key strategic assets Mellozzan and Memprex.

The event will be held at Carnegie’s premises in Stockholm, Sweden and a live webcast will be available for those who cannot attend in person.

Location: Regeringsgatan 56, 111 56 Stockholm
Date & Time: 7 March 2025, 09:00-12:00 CET

Registration: https://tinyurl.com/bddzbxnh

It will be possible to ask questions both from the audience and via webcast during the presentations.

For inquiries regarding one-on-one meetings or other event-related questions, kindly send an email to ellen.mioen@carnegie.se.

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 40 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.